GOSSAMER BIO, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
GOSSAMER BIO, INC. (GOSS) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $15.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2023-08-08
- GOSSAMER BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-06-30 was $15.00K, a 0.00% change year-over-year.
- GOSSAMER BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-06-30 was $15.00K.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month |
|---|---|---|
| 2023-06-30 | $15.00K 10-Q · filed 2023-08-08 | $30.00K 10-Q · filed 2023-08-08 |
| 2022-06-30 | $15.00K 10-Q · filed 2023-08-08 | $35.00K 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |